Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	6.34T +104.1%
Revenue (ttm)	1.55T +3.5%
Net Income	169.55B +39.8%
EPS	13,362.00 +39.7%
Shares Out	12.68M
PE Ratio	37.42
Forward PE	35.07
Dividend	1,250.00 (0.26%)
Ex-Dividend Date	Mar 30, 2026

Volume	43,997
Average Volume	81,851
Open	491,000
Previous Close	487,000
Day's Range	481,000 - 500,000
52-Week Range	225,000 - 647,000
Beta	0.62
RSI	46.15
Earnings Date	Apr 29, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2025, Hanmi Pharm.'s revenue was 1.55 trillion, an increase of 3.48% compared to the previous year's 1.50 trillion. Earnings were 169.55 billion, an increase of 39.76%.